Veracyte partners with J&J on development of lung cancer test
The deal, with J&J Innovation and the drugmaker's lung cancer initiative, includes a $5 million upfront payment and up to $15 million in milestones.
The deal, with J&J Innovation and the drugmaker's lung cancer initiative, includes a $5 million upfront payment and up to $15 million in milestones.
The next step for the company is to focus on its Percepta Bronchial Genomic Classifier - this was picked up back in 2014 when it brought in $21 million in a deal with Allegro Diagnostics. This test allows doctors to look at 23 genes in cells lining the respiratory tract to better diagnose lung cancer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.